Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

apceth Receives Approval for a Clinical Cancer Trial with Adult Mesenchymal Stem Cells

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
apceth's first innovative cellular anti-cancer drug based on modified mesenchymal stem cells enters Phase I / II of clinical testing.

apceth GmbH & Co. KG with its headquarters and manufacturing sites in Munich and Ottobrunn (near Munich) has received approval to conduct a clinical cancer trial with its genetically modified, adult mesenchymal stem cells.

This is an entirely new approach for the treatment of advanced types of cancer for which there is currently no effective treatment available.

The multicenter, open-label trial will recruit patients suffering from advanced adenocarcinomas of the gastrointestinal tract. This innovative therapy is based on mesenchymal stem cells harvested from the patient's own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient.

The stem cells thus modified specifically target the tumor and the cytotoxic gene product is selectively activated at the site of the tumor or its metastases to increase local efficacy and to reduce systemic toxicity, one of the main problems of systemic chemotherapy. This unique principle is also applicable to other cancer types.

This clinical trial will be initiated at the University Hospital Grosshadern in Munich in the next few weeks in collaboration with experts from the National Center of Tumor Diseases (NCT) in Heidelberg and the Karolinska Institute in Stockholm.

There is already broad international interest in expanding this trial and further developing this innovative therapy option.

John Marshall, Professor of Oncology and Director at the Lombardi Cancer Center of the Georgetown University in Washington, DC: "This is a very exciting new class of drugs based on adult stem cells delivering a true innovation for patients with advanced cancer. There is a clear unmet medical need for this and we are hopeful that we can begin testing in the US soon."

Also other leading cancer centers in the USA have already expressed their interest, such as the M.D. Anderson Cancer Center in Houston and the Fred Hutchinson Cancer Research Center in Seattle.

This to date unique and innovative approach in the treatment of cancer is part of apceth's corporate strategy of developing sustainable cell-based therapeutics.

Other clinical trials are already testing the treatment of advanced vascular diseases, while other cellular drugs are under development.

Besides its own internal research and development programs, apceth also collaborates with international pharmaceutical and biotech companies, who are showing increasing interest in cell- and gene therapeutics as a next-generation treatment option and entering the emerging field of "regenerative medicine".

While apceth is already being supported by numerous national and international grants, the company has just concluded another round of financing of € 22 m from their existing investors.

This will enable apceth to further develop its innovative cellular therapeutics right up to the clinical testing stage.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

apceth’s First-In-Man, First-In-Class Clinical Trial with MSCs is Now Enrolling
TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract.
Monday, January 27, 2014
apceth Names Dr Stefanos Theoharis Chief Business Officer
Dr Stefanos Theoharis will lead apceth’s business development and business operations and promote the continued expansion of apceth’s GMP manufacturing business.
Thursday, September 05, 2013
apceth Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic
Development of apceth’s first innovative “Advanced Therapy Medicinal Product” based on modified adult stem cells for cancer therapy.
Wednesday, February 06, 2013
apceth Received Extended Manufacturer's Licence for Somatic Cell Therapeutics at the Ottobrunn Site
Four new cleanrooms expand capacity to a total of 600 m2.
Tuesday, November 01, 2011
apceth Extends Top Management
Prof. Ralf Huss, previously Global Head of the Therapeutic Cell Initiative at Roche, joins the management board of apceth GmbH & Co. KG, Munich.
Monday, October 10, 2011
apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for pAOD
Study investigates tolerability and efficacy of apceth's somatic cell therapeutics for treatment of pAOD after angioplasty.
Tuesday, August 23, 2011
apceth is Granted a Manufacturer's Licence for Somatic Cell Therapy
Manufacturer's licence enables contract manufacture and development of innovative cell preparations for contractual partners.
Tuesday, August 09, 2011
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!